Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
REGISTRATION IS OPEN!
Join us in Mandelieu-La Napoule, France in February 2026
ABOUT THE CONFERENCE:
ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukemias have been published which will be discussed in various sessions.
The programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.
THE CONFERENCE MAIN SCIENTIFIC TOPICS
• Dilemmas in acute leukaemias
• Novel treatments
• Diagnosis and treatment of rare diseases and rare subsets
• Is MRD a proper surrogate endpoint in AML?
• Optimizing outcomes in acute leukemias using supportive strategies
• Immune targeting strategies in ALL
• Real-world AML therapy
• Is Blina-TKI enough to cure Ph-positive ALL?
• HSC transplantation
• Leukemia treatment challenges
THE LEARNING OBJECTIVES OF #ESHAL2026
• Knowledge of Classification of ALL and AML
• Insight in prognosis of ALL and AML
• Application of MRD
• Knowledge of established and novel treatment options in ALL and AML
• Indications of alloSCT
• Management of challenging subgroups of AML and ALL
• Controversies on clinical trials and treatment options
THE PROGRAMME WILL INCLUDE:
Plenary Sessions – KEYNOTE Lecture – Interactive Case Presentations – Roundtables Panel Discussions
Debates – Poster Walks – Meet the Expert Sessions Voting technology
Brief Oral Communications – Ample time for in-depth discussion
With the support of*: 
Major Conference Partner
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
